Literature DB >> 11250998

Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials.

A C Voogd1, M Nielsen, J L Peterse, M Blichert-Toft, H Bartelink, M Overgaard, G van Tienhoven, K W Andersen, R J Sylvester, J A van Dongen.   

Abstract

PURPOSE: Risk factors for local and distant recurrence after breast-conserving therapy and mastectomy were compared to define guidelines for the decision making between both treatments. PATIENTS AND METHODS: The data of two randomized clinical trials for stage I and II breast cancer patients were pooled. The total number of patients in the study was 1,772, of whom 879 underwent breast conservation, and 893, modified radical mastectomy. Representative slides of the primary tumor were available for histopathologic review in 1,610 cases (91%).
RESULTS: There were 79 patients with local recurrence after breast-conservation and 80 after mastectomy, the 10-year rates being 10% (95% confidence interval [CI], 8% to 13%) and 9% (95% CI, 7% to 12%), respectively. Age no more than 35 years (compared with age >60: hazard ratio [HR], 9.24; 95% CI, 3.74 to 22.81) and an extensive intraductal component (HR, 2.52; 95% CI, 1.26 to 5.00) were significantly associated with an increased risk of local recurrence after breast-conserving therapy. Vascular invasion was predictive of the risk of local recurrence, irrespective of the type of primary treatment (P <.01). Tumor size, nodal status, high histologic grade, and vascular invasion were all highly significant predictors of distant disease after breast-conserving therapy and mastectomy (P <.01). Age no more than 35 years and microscopic involvement of the excision margin were additional independent predictors of distant disease after breast-conserving therapy (P <.01).
CONCLUSION: Age no more than 35 years and the presence of an extensive intraductal component are associated with an increased risk of local recurrence after breast-conserving therapy. Vascular invasion causes a higher risk of local recurrence after mastectomy as well as after breast-conserving therapy and should therefore not be used for deciding between the two treatments.

Entities:  

Mesh:

Year:  2001        PMID: 11250998     DOI: 10.1200/JCO.2001.19.6.1688

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  115 in total

1.  Patterns and risk factors of locoregional recurrence in T1-T2 node negative breast cancer patients treated with mastectomy: implications for postmastectomy radiotherapy.

Authors:  Rita Abi-Raad; Rimoun Boutrus; Rui Wang; Andrzej Niemierko; Shannon Macdonald; Barbara Smith; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-03-21       Impact factor: 7.038

2.  Lymph node ratio is more valuable than level III involvement for prediction of outcome in node-positive breast carcinoma patients.

Authors:  Emin Yildirim; Ugur Berberoglu
Journal:  World J Surg       Date:  2007-02       Impact factor: 3.352

Review 3.  Radiation therapy after breast-conserving surgery.

Authors:  Naoyuki Shigematsu; Atsuya Takeda; Naoko Sanuki; Junichi Fukada; Takashi Uno; Hisao Ito; Osamu Kawaguchi; Etsuo Kunieda; Atsushi Kubo
Journal:  Radiat Med       Date:  2006-06

4.  Prognostic factors affecting locoregional recurrence in patients with stage IIIB noninflammatory breast cancer.

Authors:  Kaptan Gülben; Uğur Berberoğlu; Aziz Cengiz; Hüseyin Altınyollar
Journal:  World J Surg       Date:  2007-09       Impact factor: 3.352

5.  Neoadjuvant chemotherapy in invasive lobular carcinoma may not improve rates of breast conservation.

Authors:  Judy C Boughey; Jamie Wagner; Betsy J Garrett; Lori Harker; Lavinia P Middleton; Gildy V Babiera; Funda Meric-Bernstam; Anthony Lucci; Kelly K Hunt; Isabelle Bedrosian
Journal:  Ann Surg Oncol       Date:  2009-03-12       Impact factor: 5.344

Review 6.  What is a clear margin in breast conserving cancer surgery?

Authors:  Helen Krontiras; Rachael B Lancaster; Marshall M Urist
Journal:  Curr Treat Options Oncol       Date:  2014-03

7.  Protective role of LRRC3B in preventing breast cancer metastasis and recurrence post-bupivacaine.

Authors:  Gong-Sheng Li; Gao-Yin Kong; Yi Zou
Journal:  Oncol Lett       Date:  2017-08-18       Impact factor: 2.967

8.  Contralateral prophylactic mastectomy in young women with breast cancer: a population-based analysis of predictive factors and clinical impact.

Authors:  A Bouchard-Fortier; N N Baxter; R Sutradhar; K Fernandes; X Camacho; P Graham; M L Quan
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

9.  Time to breast cancer relapse predicted by primary tumour characteristics, not lymph node involvement.

Authors:  Danielle J Fitzpatrick; Christine S Lai; Robert F Parkyn; David Walters; Vladimir Humeniuk; David C A Walsh
Journal:  World J Surg       Date:  2014-07       Impact factor: 3.352

10.  Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Authors:  Meena S Moran; Stuart J Schnitt; Armando E Giuliano; Jay R Harris; Seema A Khan; Janet Horton; Suzanne Klimberg; Mariana Chavez-MacGregor; Gary Freedman; Nehmat Houssami; Peggy L Johnson; Monica Morrow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.